Results 51 to 60 of about 874,981 (155)

Xuetongsu attenuates synovial inflammation in rheumatoid arthritis by inhibiting the IL-23/IL-17/NF-κB inflammatory axis

Frontiers in Pharmacology
IntroductionPersistent synovial hyperplasia, a hallmark of rheumatoid arthritis (RA), can lead to joint deformities. During the pathogenesis of RA, the expression of IL-23 promotes Th17 cell proliferation and IL-17 production, which in turn upregulates ...
Yuxin Chen, Yasi Deng, Hao Zheng, Hao Zheng, Bin Li, Yupei Yang, Juan Huang, Hanwen Yuan, Mengyun Wang, Wei Wang, Huanghe Yu   +10 more
doaj   +1 more source

Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins

The Korean Journal of Gastroenterology
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic inflammatory disease of the gastrointestinal tract.
Seung Min Hong, Won Moon
doaj   +1 more source

Tildrakizumab in real-world Chinese psoriasis: efficacy-safety profiles from a 28-week retrospective cohort with geriatric, late-onset and metabolic syndrome stratification

Journal of Dermatological Treatment
Objective To assess the real-world efficacy and safety of tildrakizumab in Chinese patients with psoriasis stratified by age, age of psoriasis onset and MetS status.Methods This two-center retrospective cohort study evaluated tildrakizumab’s efficacy and
Qianzi Liu, Kun Hu, Yang Sha, Chengzhi Lv, Yehong Kuang   +4 more
doaj   +1 more source

Dual Role of Interleukin-23 in Epicutaneously-Sensitized Asthma in Mice

Allergology International, 2014
Background: Interleukin (IL)-23/Th17 axis plays an important role in the pathophysiology of asthma and eczema, however, there are some conflicting data about the effects of this system on allergic airway inflammation.
Katsunori Masaki, Yusuke Suzuki, Shizuko Kagawa, Motohiro Kodama, Hiroki Kabata, Jun Miyata, Kyuto Tanaka, Koichi Fukunaga, Koichi Sayama, Tsuyoshi Oguma, Tokuhiro Kimura, Masayuki Amagai, Tomoko Betsuyaku, Koichiro Asano   +13 more
doaj   +1 more source

Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)

Dermatology and Therapy
Introduction Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Francesco Loconsole, Martina Burlando, Anna E. Cagni, Norma Cameli, Carlo G. Carrera, Andrea Carugno, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Maria C. Fargnoli, Francesca M. Gaiani, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Alessandra Michelucci, Maria L. Musumeci, Diego Orsini, Romina Ortega, Luca Potestio, Luca Rapparini, Simone Ribero, Francesca Satolli, Davide Strippoli, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Pina Brianti, Antonio Costanzo, Alessandra Narcisi   +39 more
doaj   +1 more source

Signaling pathways associated with interleukins 12 and 23 and epigenetic mechanism of sequential-specific regulation of expression of related genes by miRNAs as molecular markers for assessing the potential of anti-cytokine therapies

Przegląd Dermatologiczny, 2019
The molecular targeted therapy is focused on blocking the activity of specific cytokines and the signalling cascades they activate. In the treatment of psoriasis, this type of therapy is based on treatment with anti-tumor necrosis factor drugs, anti-IL ...
Beniamin O. Grabarek, Dominika L. Wcisło-Dziadecka, Urszula Mazurek   +2 more
doaj   +1 more source

Anti-interleukin-23 treatment linked to improved Clostridioides difficile infection survival

Gut Microbes
Clostridioides difficile is a leading cause of healthcare-associated infection, and an unacceptably high proportion of patients with C. difficile infection die despite conventional antibiotic treatment. Host-directed immunotherapy has been proposed as an
Gregory R. Madden, Robert Preissner, Saskia Preissner, William A. Petri   +3 more
doaj   +1 more source

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Frontiers in Immunology
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease.
James G. Krueger, Kilian Eyerich, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, Maria T. Abreu, M. Merle Elloso, Anne Fourie, Steven Fakharzadeh, Jonathan P. Sherlock, Jonathan P. Sherlock, Ya-Wen Yang, Daniel J. Cua, Iain B. McInnes   +13 more
doaj   +1 more source

Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series

RMD Open
Background Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with cancer. However, these therapies are associated with adverse events including de novo immune-related adverse events or flare of pre-exiting autoimmune ...
Pavlos Msaouel, Adi Diab, Patrick Hwu, Sang T. Kim, Matthew Campbell, Yuanteng Jeff Li   +5 more
doaj   +1 more source

Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease

Mediators of Inflammation, 2017
Objectives. To analyze the correlation between the serum concentration of interleukin- (IL-) 23 and atherosclerotic changes, traditional atherosclerotic risk factors, the autoantibody profile, and involvement of selected organs in systemic lupus ...
Katarzyna Fischer, Hanna Przepiera-Będzak, Marcin Sawicki, Anna Walecka, Iwona Brzosko, Marek Brzosko   +5 more
doaj   +1 more source